JPWO2021181118A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021181118A5 JPWO2021181118A5 JP2022554473A JP2022554473A JPWO2021181118A5 JP WO2021181118 A5 JPWO2021181118 A5 JP WO2021181118A5 JP 2022554473 A JP2022554473 A JP 2022554473A JP 2022554473 A JP2022554473 A JP 2022554473A JP WO2021181118 A5 JPWO2021181118 A5 JP WO2021181118A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- gene therapy
- col4a4
- col4a5
- col4a3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2003618.2 | 2020-03-12 | ||
| GBGB2003618.2A GB202003618D0 (en) | 2020-03-12 | 2020-03-12 | Gene Therapy |
| PCT/GB2021/050633 WO2021181118A1 (en) | 2020-03-12 | 2021-03-12 | Gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517934A JP2023517934A (ja) | 2023-04-27 |
| JP2023517934A5 JP2023517934A5 (https=) | 2024-03-21 |
| JPWO2021181118A5 true JPWO2021181118A5 (https=) | 2024-03-21 |
Family
ID=70453740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554473A Pending JP2023517934A (ja) | 2020-03-12 | 2021-03-12 | 遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12589167B2 (https=) |
| EP (1) | EP4118216A1 (https=) |
| JP (1) | JP2023517934A (https=) |
| CN (1) | CN115427578B (https=) |
| AU (1) | AU2021234169A1 (https=) |
| BR (1) | BR112022018036A2 (https=) |
| CA (1) | CA3171232A1 (https=) |
| GB (1) | GB202003618D0 (https=) |
| IL (1) | IL296255A (https=) |
| MX (1) | MX2022011295A (https=) |
| WO (1) | WO2021181118A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| EP4273243A1 (en) | 2022-05-02 | 2023-11-08 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Nucleic acid constructs and vectors for podocyte specific expression |
| GB202304841D0 (en) * | 2023-03-31 | 2023-05-17 | Purespring Therapeutics Ltd | Promoter |
| CN116590345B (zh) * | 2023-05-06 | 2024-01-30 | 北京中医药大学 | 永生化小鼠足细胞系及其制备方法、分化方法和应用 |
| GB202309913D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome |
| GB202309908D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases |
| GB202309914D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Promoters |
| GB202309909D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Regulatory elements |
| WO2025168940A1 (en) * | 2024-02-07 | 2025-08-14 | Purespring Therapeutics Limited | Vectors |
| WO2025193938A1 (en) * | 2024-03-13 | 2025-09-18 | Oregon Health & Science University | Delivery of type iv collagen alpha chain using a split intein dual aav vector |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL332875A1 (en) | 1996-10-17 | 1999-10-25 | Oxford Biomedica Ltd | Retroviral vectors |
| US20060281090A1 (en) | 2003-05-01 | 2006-12-14 | University Of Washington Uw Tech Transfer- Invention Licensing | Capsid-modified adenovirus vectors and methods of using the same |
| WO2005012351A2 (en) | 2003-08-01 | 2005-02-10 | The Brigham And Women's Hospital, Inc. | Novel functions for decay accelerating factor (daf) in inflammation |
| EP2357254A1 (en) | 2005-02-14 | 2011-08-17 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| WO2007056435A2 (en) | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
| WO2008136547A1 (en) | 2007-05-07 | 2008-11-13 | University Of Ulsan Foundation For Industry Cooperation | Method of preventing or treating body weight disorders by employing clusterin |
| ES2457822T3 (es) | 2007-11-08 | 2014-04-29 | The General Hospital Corporation | Procedimientos y composiciones de tratamiento de enfermedades proteinúricas |
| EP2601288B1 (en) | 2010-08-05 | 2016-04-06 | Wisconsin Alumni Research Foundation | Simplified basic media for human pluripotent cell culture |
| US8852936B2 (en) | 2012-09-21 | 2014-10-07 | Laurantis Pharma Oy | Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery |
| TW201506036A (zh) | 2013-08-14 | 2015-02-16 | Laurantis Pharma Oy | Vegf-c及ccbe1之治療用途 |
| CA2955481A1 (en) | 2014-07-25 | 2016-01-28 | Goldfinch Biopharma, Inc. | Collagen iv replacement |
| EP3526333A4 (en) * | 2016-10-13 | 2020-07-29 | University of Massachusetts | AAV CAPSIDE DESIGNS |
| CN107011424B (zh) | 2017-03-14 | 2020-07-03 | 华南师范大学 | 斜带石斑鱼补体c1inh基因、载体、重组菌株和蛋白及其应用 |
| GB201706808D0 (en) | 2017-04-28 | 2017-06-14 | Univ Newcastle | Modified complement proteins and uses thereof |
| EP3635121A1 (en) * | 2017-06-02 | 2020-04-15 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders |
| CN111788311A (zh) | 2017-10-20 | 2020-10-16 | 双子治疗公司 | 用于治疗年龄相关性黄斑变性的组合物和方法 |
| RU2675861C1 (ru) | 2017-11-22 | 2018-12-25 | Лев Иосифович Шагам | Способ прогнозирования наличия мутации гена col4a5 у пациентов с предполагаемым диагнозом "синдром альпорта" |
| EP3856763A1 (en) * | 2018-09-28 | 2021-08-04 | Massachusetts Institute of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| EP3861010A1 (en) * | 2018-10-02 | 2021-08-11 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
| CA3117551A1 (en) | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| RU2714763C1 (ru) | 2018-11-08 | 2020-02-19 | Генетик Диагностикс Энд Терапи 21 Лтд | Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения |
| GB201900702D0 (en) | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| GB202010009D0 (en) | 2020-06-30 | 2020-08-12 | Syncona Investment Man Ltd | Vector |
| GB202103470D0 (en) | 2021-03-12 | 2021-04-28 | Univ Bristol | Promoter |
-
2020
- 2020-03-12 GB GBGB2003618.2A patent/GB202003618D0/en not_active Ceased
-
2021
- 2021-03-12 MX MX2022011295A patent/MX2022011295A/es unknown
- 2021-03-12 AU AU2021234169A patent/AU2021234169A1/en active Pending
- 2021-03-12 IL IL296255A patent/IL296255A/en unknown
- 2021-03-12 BR BR112022018036A patent/BR112022018036A2/pt unknown
- 2021-03-12 CN CN202180020240.6A patent/CN115427578B/zh active Active
- 2021-03-12 CA CA3171232A patent/CA3171232A1/en active Pending
- 2021-03-12 EP EP21711944.5A patent/EP4118216A1/en active Pending
- 2021-03-12 US US17/909,839 patent/US12589167B2/en active Active
- 2021-03-12 JP JP2022554473A patent/JP2023517934A/ja active Pending
- 2021-03-12 WO PCT/GB2021/050633 patent/WO2021181118A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Follenzi et al. | Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors | |
| JP2019513794A5 (https=) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| SE504074C2 (sv) | Proteinberedning för subkutan, intramuskulär eller intradermal administrering | |
| JPWO2021181118A5 (https=) | ||
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| WO1999006562A1 (en) | Method enabling readministration of aav vector via immunosuppression of host | |
| JP2004501650A5 (https=) | ||
| Driessche et al. | Viral vector-mediated gene therapy for hemophilia | |
| JP2025090820A5 (https=) | ||
| Gruntman et al. | Bridging from intramuscular to limb perfusion delivery of rAAV: optimization in a non-human primate study | |
| JP2020527167A5 (https=) | ||
| JP2021500880A5 (https=) | ||
| JPWO2020148548A5 (https=) | ||
| JP2002527483A (ja) | アデノウィルスベクターを投与する方法 | |
| Barbour | The balance of risk and benefit in gene-therapy trials | |
| JPWO2020142752A5 (https=) | ||
| JPWO2020172490A5 (https=) | ||
| JP2017530128A (ja) | 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物 | |
| JPWO2022015715A5 (https=) | ||
| JP2022514271A5 (https=) | ||
| JPWO2022186282A5 (https=) | ||
| JP2021533098A5 (https=) | ||
| JPWO2019241206A5 (https=) | ||
| JPWO2019138250A5 (https=) |